{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:54:22Z","timestamp":1789872862502,"version":"4.0.1"},"reference-count":172,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Biologic and targeted synthetic DMARDs (b\/tsDMARDs) have revolutionized the management of multiple rheumatic inflammatory conditions. Among these, polyarticular JIA (pJIA) and RA display similarities in terms of disease pathophysiology and response pattern to b\/tsDMARDs. Indeed, the therapeutic efficacy of novel targeted drugs is variable among individual patients, in both RA and pJIA. The mechanisms and determinants of this heterogeneous response are diverse and complex, such that the development of true \u2018precision\u2019-medicine strategies has proven highly challenging. In this review, we will discuss pathophysiological, patient-specific, drug-specific and environmental factors contributing to individual therapeutic response in pJIA in comparison with what is known in RA. Although some biomarkers have been identified that stratify with respect to the likelihood of either therapeutic response or non-response, few have proved useful in clinical practice so far, likely due to the complexity of treatment\u2013response mechanisms. Consequently, we propose a pragmatic, patient-centred and clinically based approach, i.e. personalized instead of biomarker-based precision medicine in JIA.<\/jats:p>","DOI":"10.1093\/rheumatology\/kead490","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T16:56:08Z","timestamp":1695142568000},"page":"594-607","source":"Crossref","is-referenced-by-count":9,"title":["Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-3820","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Triaille","sequence":"first","affiliation":[{"name":"P\u00f4le de Pathologies Rhumatismales Syst\u00e9miques et Inflammatoires, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain , Brussels, Belgium"},{"name":"Department of Pediatric Hematology, Oncology, Immunology and Rheumatology, Cliniques Universitaires Saint-Luc , Brussels, Belgium"},{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-549X","authenticated-orcid":false,"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP , Paris, France"},{"name":"Universit\u00e9 Paris-Cit\u00e9 , Paris, France"},{"name":"Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No. 739543"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"De Somer","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven , Leuven, Belgium"},{"name":"Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No. 739543"},{"name":"Department of Microbiology and Immunology, University of Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-5672","authenticated-orcid":false,"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[{"name":"P\u00f4le de Pathologies Rhumatismales Syst\u00e9miques et Inflammatoires, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain , Brussels, Belgium"},{"name":"Department of Rheumatology, Cliniques Universitaires Saint-Luc , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard R","family":"Lauwerys","sequence":"additional","affiliation":[{"name":"P\u00f4le de Pathologies Rhumatismales Syst\u00e9miques et Inflammatoires, Institut de Recherche Exp\u00e9rimentale et Clinique, Universit\u00e9 Catholique de Louvain , Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[{"name":"Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No. 739543"},{"name":"Department of Rheumatology, University Hospitals Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford , Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Wouters","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, University Hospitals Leuven , Leuven, Belgium"},{"name":"Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP , Paris, France"},{"name":"Member of the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases \u2013 Project ID No. 739543"},{"name":"Department of Microbiology and Immunology, University of Leuven , Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"2024030205490110200_kead490-B1","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","article-title":"The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort","volume":"74","author":"Guzman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B2","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2665-9913(20)30025-4","article-title":"Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study","volume":"2","author":"Kearsley-Fleet","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024030205490110200_kead490-B3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12969-022-00682-x","article-title":"Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study","volume":"20","author":"Grazziotin","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024030205490110200_kead490-B4","doi-asserted-by":"crossref","first-page":"16195","DOI":"10.1038\/s41598-021-95252-8","article-title":"Persistence and adherence to biologic therapies in juvenile idiopathic arthritis","volume":"11","author":"Nieto-Gonzalez","year":"2021","journal-title":"Sci Rep"},{"key":"2024030205490110200_kead490-B5","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","article-title":"Biological classification of childhood arthritis: roadmap to a molecular nomenclature","volume":"17","author":"Nigrovic","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2024030205490110200_kead490-B6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward New classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"2024030205490110200_kead490-B7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.40350","article-title":"Review: genetics and the classification of arthritis in adults and children","volume":"70","author":"Nigrovic","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41584-022-00814-3","article-title":"How does age determine the development of human immune-mediated arthritis?","volume":"18","author":"Degboe","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2024030205490110200_kead490-B9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/rheumatology\/key306","article-title":"Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B10","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3899\/jrheum.200437","article-title":"Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"48","author":"Mannion","year":"2021","journal-title":"J Rheumatol"},{"key":"2024030205490110200_kead490-B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/annrheumdis-2021-220853","article-title":"Baseline predictors of different types of treatment success in rheumatoid arthritis","volume":"81","author":"Capelusnik","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jbspin.2018.02.001","article-title":"Switching of biologics in RA patients who do not respond to the first biologic","volume":"85","author":"Durez","year":"2018","journal-title":"Joint Bone Spine"},{"key":"2024030205490110200_kead490-B16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2024030205490110200_kead490-B17","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/art.23291","article-title":"Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers","volume":"58","author":"Nistala","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B18","doi-asserted-by":"crossref","first-page":"108484","DOI":"10.1016\/j.clim.2020.108484","article-title":"IL-21(+) CD4(+) T helper cells co-expressing IFN-gamma and TNF-alpha accumulate in the joints of antinuclear antibody positive patients with juvenile idiopathic arthritis","volume":"217","author":"Fischer","year":"2020","journal-title":"Clin Immunol"},{"key":"2024030205490110200_kead490-B19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/annrheumdis-2015-208992","article-title":"TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis","volume":"76","author":"Rossetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/kep125","article-title":"Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis","volume":"48","author":"van den Ham","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"de Jager","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B22","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2024030205490110200_kead490-B23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1136\/ard.2010.148635","article-title":"Synovial membrane immunohistology in early untreated juvenile idiopathic arthritis: differences between clinical subgroups","volume":"70","author":"Finnegan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/rheumatology\/kel225","article-title":"Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration","volume":"46","author":"Gregorio","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/annrheumdis-2016-210025","article-title":"Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases","volume":"76","author":"Hinks","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B26","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1172\/JCI96107","article-title":"PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation","volume":"128","author":"Petrelli","year":"2018","journal-title":"J Clin Invest"},{"key":"2024030205490110200_kead490-B27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1529-0131(200004)43:4<765::AID-ANR7>3.0.CO;2-B","article-title":"Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis","volume":"43","author":"Wedderburn","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.30093","article-title":"Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production","volume":"63","author":"van Hamburg","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B30","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/art.23505","article-title":"Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype","volume":"58","author":"Thurlings","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"2024030205490110200_kead490-B32","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41467-021-22975-7","article-title":"Conserved human effector Treg cell transcriptomic and epigenetic signature in arthritic joint inflammation","volume":"12","author":"Mijnheer","year":"2021","journal-title":"Nat Commun"},{"key":"2024030205490110200_kead490-B33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/annrheumdis-2014-206226","article-title":"A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment","volume":"75","author":"Spreafico","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B34","doi-asserted-by":"crossref","first-page":"851532","DOI":"10.3389\/fmed.2022.851532","article-title":"B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?","volume":"9","author":"Moura","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024030205490110200_kead490-B35","doi-asserted-by":"crossref","first-page":"7960","DOI":"10.3390\/ijms22157960","article-title":"Signals and mechanisms regulating monocyte and macrophage activation in the pathogenesis of juvenile idiopathic arthritis","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024030205490110200_kead490-B36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10875-011-9580-0","article-title":"T-cell compartment in synovial fluid of pediatric patients with JIA correlates with disease phenotype","volume":"31","author":"Amariglio","year":"2011","journal-title":"J Clin Immunol"},{"key":"2024030205490110200_kead490-B37","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/kei025","article-title":"Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study","volume":"44","author":"Peake","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B38","doi-asserted-by":"crossref","first-page":"109902","DOI":"10.1016\/j.celrep.2021.109902","article-title":"Arthritis flares mediated by tissue-resident memory T cells in the joint","volume":"37","author":"Chang","year":"2021","journal-title":"Cell Rep"},{"key":"2024030205490110200_kead490-B39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"2024030205490110200_kead490-B40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"key":"2024030205490110200_kead490-B41","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm.3897","article-title":"Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies","volume":"21","author":"Cho","year":"2015","journal-title":"Nat Med"},{"key":"2024030205490110200_kead490-B42","doi-asserted-by":"crossref","first-page":"e00035","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2024030205490110200_kead490-B43","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/bloodadvances.2017014449","article-title":"Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis","volume":"2","author":"Silva","year":"2018","journal-title":"Blood Adv"},{"key":"2024030205490110200_kead490-B44","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.22656","article-title":"Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial","volume":"56","author":"Brinkman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B45","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2021-220043","article-title":"Preclinical models of arthritis for studying immunotherapy and immune tolerance","volume":"80","author":"Meehan","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B46","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/art.21119","article-title":"Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis","volume":"52","author":"Viola","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/art.27740","article-title":"Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants","volume":"63","author":"Smolen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B49","first-page":"5","article-title":"Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight\u2013Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. Arthritis","volume":"74","author":"Felson","year":"2022","journal-title":"& Rheumatology"},{"key":"2024030205490110200_kead490-B50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/ard.57.1.38","article-title":"Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group","volume":"57","author":"Ruperto","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B51","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B52","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/rheumatology\/ket470","article-title":"Definition of improvement in juvenile idiopathic arthritis using the juvenile arthritis disease activity score","volume":"53","author":"Horneff","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B53","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B54","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/art.41879","article-title":"Definition and validation of the American College of Rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis","volume":"73","author":"Trincianti","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B55","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","article-title":"Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"58","author":"Doeleman","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B56","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/rheumatology\/keac335","article-title":"Trajectories of disease activity in patients with JIA in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"62","author":"Shiff","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B57","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/annrheumdis-2021-220202","article-title":"Primary and secondary non-response: in need of operational definitions in observational studies","volume":"80","author":"Vallejo-Yague","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13075-016-0919-z","article-title":"Higher expression of TNFalpha-induced genes in the synovium of patients with early rheumatoid arthritis correlates with disease activity, and predicts absence of response to first line therapy","volume":"18","author":"De Groof","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B59","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"2024030205490110200_kead490-B60","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2024030205490110200_kead490-B62","doi-asserted-by":"crossref","first-page":"e000870","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open"},{"key":"2024030205490110200_kead490-B63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/tpj.2017.26","article-title":"Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis","volume":"17","author":"Bek","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"2024030205490110200_kead490-B64","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcph.1341","article-title":"FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis","volume":"59","author":"Jimenez Morales","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2024030205490110200_kead490-B65","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/acr.24471","article-title":"Data-driven patient clustering and differential clinical outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024030205490110200_kead490-B66","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/annrheumdis-2021-221163","article-title":"Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study","volume":"81","author":"Balsa","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B68","doi-asserted-by":"crossref","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","article-title":"Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view","volume":"288","author":"Hu","year":"2013","journal-title":"J Biol Chem"},{"key":"2024030205490110200_kead490-B69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-alpha agents - Comparison among therapeutic TNF-alpha antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"2024030205490110200_kead490-B70","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002216","article-title":"Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider","volume":"8","author":"Krieckaert","year":"2022","journal-title":"RMD Open"},{"key":"2024030205490110200_kead490-B71","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.2009.112847","article-title":"Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study","volume":"69","author":"Bartelds","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B73","first-page":"819","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","article-title":"Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis","volume":"79","author":"Klein","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/RHU.0000000000001835","article-title":"Genetic variants and therapeutic response to anti-TNF-alpha agents in juvenile idiopathic arthritis: an updated systematic review and meta-analysis","volume":"28","author":"Pregnolato","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2024030205490110200_kead490-B77","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S2352-4642(19)30188-9","article-title":"Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions","volume":"3","author":"Shoop-Worrall","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"2024030205490110200_kead490-B78","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3899\/jrheum.180456","article-title":"Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort","volume":"46","author":"Guzman","year":"2019","journal-title":"J Rheumatol"},{"key":"2024030205490110200_kead490-B79","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1093\/rheumatology\/key148","article-title":"Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study","volume":"57","author":"van Dijkhuizen","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B80","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1002\/art.38875","article-title":"The biologic basis of clinical heterogeneity in juvenile idiopathic arthritis","volume":"66","author":"Eng","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2018-214354","article-title":"Machine learning identifies an immunological pattern associated with multiple juvenile idiopathic arthritis subtypes","volume":"78","author":"Van Nieuwenhove","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B82","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12969-021-00553-x","article-title":"Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline","volume":"19","author":"Ganeva","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024030205490110200_kead490-B83","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","article-title":"Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis","volume":"71","author":"Bulatovic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B84","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/art.41516","article-title":"Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis","volume":"73","author":"Tao","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B85","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/art.39590","article-title":"Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis","volume":"68","author":"Plant","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B86","doi-asserted-by":"crossref","first-page":"13845","DOI":"10.1073\/pnas.1524056113","article-title":"Epipolymorphisms associated with the clinical outcome of autoimmune arthritis affect CD4+ T cell activation pathways","volume":"113","author":"Spreafico","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024030205490110200_kead490-B87","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jaut.2018.12.004","article-title":"Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking","volume":"98","author":"Nii","year":"2019","journal-title":"J Autoimmun"},{"key":"2024030205490110200_kead490-B88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.120753","article-title":"Methotrexate and injectable tumor necrosis factor-alpha inhibitor adherence and persistence in children with rheumatic diseases","volume":"40","author":"Ringold","year":"2013","journal-title":"J Rheumatol"},{"key":"2024030205490110200_kead490-B89","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2665-9913(22)00186-2","article-title":"Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial","volume":"4","author":"Lend","year":"2022","journal-title":"The Lancet Rheumatology"},{"key":"2024030205490110200_kead490-B90","doi-asserted-by":"crossref","first-page":"1759720X19844632","DOI":"10.1177\/1759720X19844632","article-title":"The role of microbiome in rheumatoid arthritis treatment","volume":"11","author":"Bodkhe","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024030205490110200_kead490-B91","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B92","first-page":"1219","article-title":"In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption","volume":"77","author":"Matsuura","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B93","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: the concentration-effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B94","doi-asserted-by":"crossref","first-page":"726490","DOI":"10.3389\/fphar.2021.726490","article-title":"Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study","volume":"12","author":"Gharib","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024030205490110200_kead490-B95","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2024030205490110200_kead490-B96","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.jaut.2020.102405","article-title":"Precision medicine and management of rheumatoid arthritis","volume":"110","author":"Aletaha","year":"2020","journal-title":"J Autoimmun"},{"key":"2024030205490110200_kead490-B97","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","article-title":"State-of-the-art: rheumatoid arthritis","volume":"69","author":"McInnes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B98","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard-2022-223349","article-title":"Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B99","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B100","doi-asserted-by":"crossref","first-page":"m2288","DOI":"10.1136\/bmj.m2288","article-title":"Comparative effectiveness of biological medicines in rheumatoid arthritis: systematic review and network meta-analysis including aggregate results from reanalysed individual patient data","volume":"370","author":"Janke","year":"2020","journal-title":"BMJ"},{"key":"2024030205490110200_kead490-B101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B102","doi-asserted-by":"crossref","first-page":"724895","DOI":"10.3389\/fimmu.2021.724895","article-title":"Common transcriptomic effects of abatacept and other DMARDs on rheumatoid arthritis synovial tissue","volume":"12","author":"Triaille","year":"2021","journal-title":"Front Immunol"},{"key":"2024030205490110200_kead490-B103","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B104","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B105","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI124611","article-title":"Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases","volume":"129","author":"Agache","year":"2019","journal-title":"J Clin Invest"},{"key":"2024030205490110200_kead490-B106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fmed.2019.00046","article-title":"Synovial tissue: turning the page to precision medicine in arthritis","volume":"6","author":"Triaille","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2024030205490110200_kead490-B107","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41584-020-0491-4","article-title":"Transforming clinical trials in rheumatology: towards patient-centric precision medicine","volume":"16","author":"Pitzalis","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2024030205490110200_kead490-B108","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B109","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/BOR.0b013e32835fd8eb","article-title":"New learnings on the pathophysiology of RA from synovial biopsies","volume":"25","author":"Pitzalis","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"2024030205490110200_kead490-B110","doi-asserted-by":"crossref","first-page":"e0122104","DOI":"10.1371\/journal.pone.0122104","article-title":"Heterogeneity of synovial molecular patterns in patients with arthritis","volume":"10","author":"Lauwerys","year":"2015","journal-title":"PLoS One"},{"key":"2024030205490110200_kead490-B111","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/annrheumdis-2011-200490","article-title":"Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis","volume":"71","author":"Schoels","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B112","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-015-0630-5","article-title":"Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial","volume":"17","author":"Manders","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B113","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B114","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard-2022-222835","article-title":"After JAK inhibitor failure: to cycle or to switch, that is the question \u2013 data from the JAK-pot collaboration of registries","volume":"82","author":"Pombo-Suarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/art.37853","article-title":"Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts","volume":"65","author":"Lee","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B116","doi-asserted-by":"crossref","first-page":"593083","DOI":"10.3389\/fimmu.2020.593083","article-title":"Paired rheumatoid arthritis synovial biopsies from small and large joints show similar global transcriptomic patterns with enrichment of private specificity TCRB and TCR signaling pathways","volume":"11","author":"Triaille","year":"2020","journal-title":"Front Immunol"},{"key":"2024030205490110200_kead490-B117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.62.7.635","article-title":"Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis","volume":"62","author":"Smeets","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B118","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224068","article-title":"Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis","author":"Triaille","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B119","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2012-203130","article-title":"What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review","volume":"73","author":"van Nies","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B120","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1136\/annrheumdis-2021-220857","article-title":"Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial","volume":"82","author":"Stouten","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B121","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/art.20811","article-title":"Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis","volume":"52","author":"Kasperkovitz","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B122","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar1780","article-title":"Pathogenesis of rheumatoid arthritis: how early is early?","volume":"7","author":"Firestein","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B123","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa2004114","article-title":"RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares","volume":"383","author":"Orange","year":"2020","journal-title":"N Engl J Med"},{"key":"2024030205490110200_kead490-B124","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/jpm12081265","article-title":"Pharmacogenomics of monoclonal antibodies for the treatment of rheumatoid arthritis","volume":"12","author":"Lim","year":"2022","journal-title":"J Pers Med"},{"key":"2024030205490110200_kead490-B125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7150\/ijms.22812","article-title":"A FCGR3A polymorphism predicts anti-drug antibodies in chronic inflammatory bowel disease patients treated with anti-TNF","volume":"15","author":"Romero-Cara","year":"2018","journal-title":"Int J Med Sci"},{"key":"2024030205490110200_kead490-B126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3390\/jpm11060573","article-title":"Influence of the FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis","volume":"11","author":"Marquez Pete","year":"2021","journal-title":"J Pers Med"},{"key":"2024030205490110200_kead490-B127","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(18)30265-6","article-title":"Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease","volume":"3","author":"Atreya","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024030205490110200_kead490-B128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/tpj.2016.88","article-title":"Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis","volume":"18","author":"Maldonado-Montoro","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"2024030205490110200_kead490-B129","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B131","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2020-216996","article-title":"Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD","volume":"79","author":"Ulijn","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B132","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13063-021-05358-7","article-title":"Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial","volume":"22","author":"Wientjes","year":"2021","journal-title":"Trials"},{"key":"2024030205490110200_kead490-B133","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American college of rheumatology\/arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B134","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3899\/jrheum.160197","article-title":"Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCh-out cohort","volume":"44","author":"Guzman","year":"2017","journal-title":"J Rheumatol"},{"key":"2024030205490110200_kead490-B136","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"2024030205490110200_kead490-B137","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B138","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1093\/rheumatology\/keab021","article-title":"Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B139","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2024030205490110200_kead490-B140","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/annrheumdis-2012-203046","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","volume":"73","author":"Horneff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B141","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"2024030205490110200_kead490-B142","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B143","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial","volume":"74","author":"Brunner","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B144","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"2024030205490110200_kead490-B145","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"2024030205490110200_kead490-B146","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2011-201060","article-title":"Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B147","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/acr.24727","article-title":"Effectiveness and safety of high-dose biologics in juvenile idiopathic arthritis in the childhood arthritis and rheumatology research alliance","volume":"74","author":"Correll","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024030205490110200_kead490-B148","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024030205490110200_kead490-B149","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/rheumatology\/kez285","article-title":"Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review","volume":"59","author":"Verstegen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B150","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/acr.21698","article-title":"Parents' preferences for drug treatments in juvenile idiopathic arthritis: a discrete choice experiment","volume":"64","author":"Burnett","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024030205490110200_kead490-B151","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11926-015-0514-3","article-title":"How important is mode of administration in treatments for rheumatic diseases and related conditions?","volume":"17","author":"Bansback","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2024030205490110200_kead490-B152","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B153","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B154","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/ard-2022-222679","article-title":"Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring","volume":"81","author":"Smeele","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B155","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B156","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/BOR.0000000000000620","article-title":"Predicting disease severity and remission in juvenile idiopathic arthritis: are we getting closer?","volume":"31","author":"Guzman","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2024030205490110200_kead490-B157","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B158","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-018-1571-6","article-title":"Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study","volume":"20","author":"Rypdal","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024030205490110200_kead490-B159","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12969-021-00607-0","article-title":"Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach","volume":"19","author":"Castillo-Vilella","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024030205490110200_kead490-B160","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1136\/annrheumdis-2014-205265","article-title":"Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review","volume":"74","author":"van Dijkhuizen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024030205490110200_kead490-B161","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00296-018-4062-9","article-title":"Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment","volume":"38","author":"Nalbanti","year":"2018","journal-title":"Rheumatol Int"},{"key":"2024030205490110200_kead490-B162","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/acr2.11468","article-title":"Identifying Factors Associated With Treatment Response in Rheumatoid Arthritis Clinical Trials","volume":"4","author":"Cordisco","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2024030205490110200_kead490-B163","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.41056","article-title":"Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers","volume":"71","author":"Guan","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024030205490110200_kead490-B164","doi-asserted-by":"crossref","first-page":"e1002750","DOI":"10.1371\/journal.pmed.1002750","article-title":"Patterns of joint involvement in juvenile idiopathic arthritis and prediction of disease course: A prospective study with multilayer non-negative matrix factorization","volume":"16","author":"Eng","year":"2019","journal-title":"PLoS Med"},{"key":"2024030205490110200_kead490-B165","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab631","article-title":"The susceptibility of attaining and maintaining DMARD-free remission in different (rheumatoid) arthritis phenotypes","author":"Luurssen-Masurel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2024030205490110200_kead490-B166","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","article-title":"The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis","volume":"43","author":"Kroot","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2024030205490110200_kead490-B167","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00296-021-05086-w","article-title":"Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study","volume":"42","author":"Nakayama","year":"2022","journal-title":"Rheumatol Int"},{"key":"2024030205490110200_kead490-B168","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/1756-185X.14699","article-title":"Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: post-hoc analysis of clinical trials","volume":"26","author":"Tanaka","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2024030205490110200_kead490-B169","doi-asserted-by":"crossref","first-page":"E808","DOI":"10.1016\/S2665-9913(21)00252-6","article-title":"Precision medicine in juvenile idiopathic arthritis\u2014has the time arrived?","volume":"3","author":"Reiff","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024030205490110200_kead490-B170","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(20)32652-0","article-title":"Precision medicine in rheumatology: are we getting closer?","volume":"397","author":"Poddubnyy","year":"2021","journal-title":"Lancet"},{"key":"2024030205490110200_kead490-B171","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/14636778.2019.1637720","article-title":"Contested futures: envisioning \u201cPersonalized,\u201d \u201cStratified,\u201d and \u201cPrecision\u201d medicine","volume":"38","author":"Erikainen","year":"2019","journal-title":"New Genet Soc"},{"key":"2024030205490110200_kead490-B172","doi-asserted-by":"crossref","first-page":"1759720X221114101","DOI":"10.1177\/1759720X221114101","article-title":"Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes","volume":"14","author":"Taylor","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead490\/52209389\/kead490.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/3\/594\/56818646\/kead490.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/3\/594\/56818646\/kead490.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T05:50:02Z","timestamp":1709358602000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/3\/594\/7277195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":172,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,19]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead490","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,1]]},"published":{"date-parts":[[2023,9,19]]}}}